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Abstract 
Endometrial stromal sarcomas (ESS) are rare and understudied gynaecological 
mesenchymal neoplasms. These tumours can be confused with many other 
gynaecological and not-gynaecological tumours due to their variegated 
morphological appearance and non-specific immunohistochemical profile.  
ESS can express cytokeratin and, therefore, may be misdiagnosed as carcinoma 
especially in extra-uterine locations and when recurrence/metastasis is present.  
In this study, we investigated the expression of a wide spectrum of cytokeratins 
consisting of AE1/3, CAM5.2, HMCK, MNF116, CK5, CK6, CK7, CK8/18, CK14, 
CK17, CK19, and CK20 in six low grade (LG) and five high-grade (HG) ESS. 
Additionally, staining for Oestrogen Receptor (ER), Progesterone Receptor (PR), 
CD10 and Cyclin D1 was performed.  
Our results showed that CKs AE1/3, CM 5.2, MNF116 and CK8/18 are more 
expressed in LGESS while HGESS express more AE1/3 and CM 5.2. 
In problematic cases, especially in recurrences or metastases, the 
immunohistochemical panel of antibodies AE1/3, MNF116, CAM 5.2 and CK8/18, 
together with other classic immunohistochemical markers CD10, Cyclin D1, ER and 
PR, may be helpful in the differential diagnosis between ESS and other 
gynaecological and non-gynaecological malignancies.  
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Introduction 
 
Endometrial stromal sarcomas (ESS) are rare mesenchymal neoplasms of the 
uterus and constitute approximately 10% of uterine mesenchymal tumours (1). 
Approximately 50% of ESSs occur in premenopausal women and the majority, 
according to the International Federation of Gynaecology and Obstetrics (FIGO), are 
stage I disease (2). Grading of ESS is of paramount importance because it can 
protect patients with low-grade ESS against overtreatment with radiotherapy and 
inappropriate, potentially dangerous systemic chemotherapy.  
The latest WHO classification divides ESS into low-grade (LG), high grade (HG) and 
undifferentiated uterine sarcoma (UUS) sub-types (3).  
Morphologically LGESS consists of cells, which resemble those of the normal 
proliferative phase of endometrial stroma. HGESSs are neoplasms consisting of 
atypical cells reminiscent of endometrial stromal cells, but lacking the degree of 
pleomorphism necessary for a diagnosis of UUS (1).  
The expression of some sub-types of cytokeratins (CKs) in ESS has been reported 
(4, 5). However, only one study investigated the expression of a relatively wide 
spectrum of CKs in ESS (6).   
The aim of this study was to analyse the expression of a broad spectrum of common 
CKs antibodies in a series of LG and HG ESS in order to evaluate whether these 
express the same subtypes of CKs. The relationship of CKs expression with CD10, 
Oestrogen Receptor (ER), Progesterone Receptor (PR) and cyclin D1 was also 
investigated.  
 
 
  
Methods 
The pathology database of a general community hospital were searched for all cases 
of uterine LG and HG ESS between 2010 and 2013 and eleven cases were retrieved.  
All cases arose in corpus uteri. Haematoxylin and eosin stained (H&E) slides were 
concomitantly reviewed by two authors (SR&CM). The cases were classified as LG 
and HG according to 2014 WHO classification. Histological features for differentiating 
LG from HG neoplasms were a grade of nuclear atypia, necrosis and pattern of 
myometrial invasion. Both LG and HG lesions showed resemblance to the proliferative 
phase of endometrial stroma. 
Based on morphology and immunohistochemistry LGESS were differentiated from 
HGESS, gland-poor adenomyosis, cellular leiomyoma, intravascular leiomyomatosis, 
leiomyosarcoma with extensive intravascular component, uterine tumours 
resembling ovarian sex cord tumour (UTROSCT), adenosarcoma and perivascular 
epithelioid cell tumour (PEComa).  
HGESS were distinguished from LGESS, carcinosarcoma, leiomyosarcoma and 
undifferentiated uterine sarcoma (UUS). No case showed a biphasic pattern of 
growth. 
Uterine tumours resembling ovarian sex cord tumour (UTROSCT) were not included 
in this study. 
Clinical data were reviewed from all patients and consisted of age, surgical treatment 
and adjuvant therapies. The Stage at disease presentation was determined 
according to FIGO and by reviewing pathology reports of a primary tumour. The 
pathological stage was reported for all patients.  
  
The study was approved by the Proportionate Review Sub-Committee of the Wales 
REC 6 (REC reference 16/WA/0079).  
Immunohistochemistry 
Serial sections at 3.5 μm were cut from Formalin Fixed Paraffin Embedded (FFPE) 
tissue blocks, mounted onto adhesive slides (Surgipath Snowcoat) and dried at 65ºC 
for 15 minutes. Each series of sections were stained on Bond III Automated 
Immunohistochemistry System Leica Stainer using Leica Bond Polymer Refine 
detection with a DAB chromogen (0.5% Copper Sulphate in PBS buffer). All antigen 
retrieval methods were performed on-board, following Queen Alexandra Hospital 
laboratory protocols, using antigen-unmasking solutions: Epitope Retrieval Solution 1 
(ER1) at pH 6.0 (Leica, AR9961) and Epitope Retrieval Solution 2 (ER2) at pH 9.0 
(Leica, AR9640) for 20 minutes. Each run included a positive control (normal 
endometrium) and a negative control where the primary antibody was omitted. 
Cytokeratin markers tested were, as follows: AE1/3, CAM5.2, HMWCK, MNF116, 
CK5, CK6, CK7, CK8/18, CK14, CK17, CK19 and CK20. Additionally, staining for ER, 
PR, CD10 and Cyclin D1 was performed. Details of antibodies (sources, clones, 
working dilutions and antigen retrieval pre-treatment) are summarised in Table 2. 
The staining was assessed with a semi-quantitative method as shown in Table 3. 
Results 
The mean age of patients in both groups was 63 years (median 62 years, range 35 
years). Six patients had LGESS (Fig. 1a, case 3) and five patients had HGESS (Fig. 
1b, case 11). Two patients with LGESS were FIGO STAGE IA, one was stage IB, one 
was stage IIB, one was IIIA and one patient showed pelvic recurrence, after 49 years, 
of uterine “malignant haemangiopericytoma”.  
  
One patient with HGESS was FIGO stage IA, one was stage IB, one was IIIB and two 
were stage IVA. 
The clinicopathological data are summarised in Table 1. 
Immunohistochemistry  
CKs expression in LGESS:  
All cases except one (case 4) were positive with AE1/3 (Fig. 2a) and CAM 5.2. Four 
cases (cases 1, 2, 5 and 6) were positive with MNF116 (Fig. 2b) and two cases 
(cases 3 and 4) were negative. 
All cases except one (case 1) were negative with CK6. Three cases (cases 1, 5 and 
6) were positive with CK 8/18 (Fig. 2c) and three cases (cases 2, 3 and 4) were 
negative. 
CKs expression in HGESS: 
Three cases (cases 7, 9 and 11) were positive with AE1/3 and two cases (cases 8 
and 10) were negative. All cases except one (case 10) were positive with CAM 5.2 
(fig. 3).   
All cases except one (case 11) were negative with MNF116 and all cases except one 
(case 9) were negative with CK6 and CK 8/18. 
All LG and HG ESSs were negative with CKs 5, 7, 14, 17, 19, 20 and HMWCK.  
In all cases of LG and HG ESSs, the staining of CKs was cytoplasmic. The extension 
and intensity were different among cases.  
CD10 was positive in all LG and HG ESSs. Nevertheless, not all cases showed 
diffuse staining. 
All LGESSs demonstrated positive immunostaining with ER and PR except case 4 
which was negative for ER. Interestingly this case showed also negative staining 
with all CKs. 
  
Three HGESSs (cases 7, 9 and 10) were negative with ER and PR while two 
HGESSs (cases 8 and 11) were positive. 
Cyclin D1 was positive in all HGESSs and negative in all LGESSs. 
No relationship was found between the expression of CKs and ER, PR and Cyclin 
D1.  
The results of immunohistochemical findings are shown in Table 4. 
Discussion 
In this study, we showed that, among the broad spectrum of CKs, the most 
diagnostically useful for both LG and HG ESS were AE1/3, MNF116, CAM 5.2 and 
CK8/18. There was no a significant difference between LG and HG ESS in terms of 
expression of CKs subtypes. 
Immunohistochemically, CD10 is routinely used for diagnosis of endometrial stromal 
tumours, but it is well known that this antibody is not specific for the diagnosis of 
ESS (8, 9). Furthermore, some ESS may also show no immunoreactivity with CD10 
(10).  
Although the histological diagnosis of the classic type of LGESS is usually simple 
and straightforward, problematic cases also exist. Some ESS may show epithelioid 
morphology (11) with the presence of glands, pseudo-papillae (12) and cord-like 
structures (13). 
LGESS may present different genetic rearrangements such as JAZF1-SUZ12, 
JAZF1-PHF1, EPC1-PHF1, MEAF6-PHF1, ZC3H7B-BCOR and MBTD1-CXorf67 
(14-16), but a sub-group of LGESS, with classic morphology and immunoprofile, 
shows no known and definite genetic aberration (17). In contrast to LGESS, the 
diagnosis of HGESS is more challenging. Some HGESS can show intratumoural 
morphological variability with areas of LGESS which, contrary to HGESS, can show 
  
positive immunostaining for ER and negative staining for Cyclin D1. None of the 
cases of HGESS reported herein showed convincing evidence of the presence of 
LGESS. 
The relatively recent recognition of a subgroup of ESS with YWHAE-NUTM2 gene 
rearrangement and complex morphology supports the existence of a category of 
ESS which is morphologically HG and seems to have an intermediate prognosis 
between LGESS and UUS (18). It is worth mentioning that none of the HGESS in 
this study showed the morphology of YWHAE-NUTM2 positive HGESS such as the 
presence of round cells arranged in nests with a delicate stromal capillary network 
and cytologically bland and mitotically active spindle cell component with a 
fibrous/fibromyxoid stroma. 
In surgical resection specimens, when a sufficient amount of tissue is available for 
histological analysis, the differential diagnosis between ESS and leiomyoma (cellular 
variant), leiomyosarcoma, adenocarcinoma with spindle cell morphology, and 
endometrioid adenocarcinoma arising in atypical polypoid adenomyoma should 
usually not be problematic. One should bear in mind that some morphological 
features of spindle cell endometrioid adenocarcinoma such as corded and hyalinised 
areas can also be present in ESS. In the above mentioned malignancies, for the 
differential diagnosis with ESS, immunohistochemical analysis of cytokeratins would 
not be as useful as morphological characteristics and possible molecular 
investigation findings. The classical vascular architecture and the pattern of invasion 
of ESS are important clues for making correct diagnosis.  
In bioptic tissue when the classical morphology of ESS such as typical vascular 
architecture and the pattern of invasion is not present, diagnosis could be difficult. 
  
The diagnosis of metastatic or recurrent ESS is even more complex, because of the 
occurrence of different morphology from an original tumour (19).  
In addition, due to its non-specificity, positive immunostaining for CD10 is not entirely 
reliable. In these cases the immunohistochemical panel of cytokeratins AE1/3, 
MNF116, CAM5.2, CK8-18 could be useful for rendering correct diagnosis of ESS. 
The molecular investigation is an expensive and time-consuming method, however, 
when suitable, should be performed. The data from the literature show that not all 
cases of ESS (LG and HG) harbour genetic fusion.  
Our findings partly confirm the previous results by Adegboyega et al (6). However, 
none of our cases expressed CK19. This may be due to the different clone of an 
antibody or technical process used in the study of Adegboyega et al.  
ESS is a very rare neoplasm, and although, theoretically, eleven cases could 
represent a reasonable number, the findings reported herein are still insufficient for 
definite conclusions and other studies with a large number of cases are warranted to 
confirm our data.  
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Figures legend 
Fig. 1a LG ESS, case 3 
Fig. 1b HG ESS, case 11 
Fig. 2a Expression of AE1/3 in LG ESS (case 6) 
Fig. 2b Expression of MNF116 in LG ESS (case 5) 
Fig. 2c Expression of CK8-18 in LG ESS (case 5) 
Fig. 3 Expression of CAM 5.2 in HG ESS (case 11) 
 
